Blog Category: Medication

New Study of Antipsychotic Use in Dementia

Call for guidelines for the use of antipsychotic drugs by people with dementia in nursing homes. New study suggests regular scrutiny of prescriptions and targeted education for physicians and nurses. [more…]…

Diabetes Screening Inadequate in Mentally Ill

New research shows that despite long-standing recommendations that severely mentally ill patients who take antipsychotics undergo annual screening for diabetes and other metabolic disorders, only 30% receive such screening. A recent research letter in JAMA Internal Medicine described a retrospective …

Atypical Antipsychotic Shows Promise for New MDD Subtype

New to the diagnosis of major depressive disorder as of DSM-5 is the specifier “with mixed features.” According to DSM-5, “specifiers provide an opportunity to define a more homogeneous subgrouping of individuals with the disorder who share certain features (e.g., …

Long-Acting Injectable Antipsychotic To Prevent Relapse in First Episode Schizophrenia

Research published in JAMA Psychiatry demonstrated that long-acting, injectable, second-generation antipsychotic medication has tremendous potential to bring clinical stability to persons with first-episode schizophrenia. According to the authors, “long-acting medications are rarely used following a first episode of schizophrenia.”

Patients …

Task Force Report on Antidepressant Use in Bipolar Disorders

The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders has been published in the American Journal of Psychiatry. The task force commented that there is “striking incongruity between the wide use of …

APA Joins ‘Choosing Wisely’ Project With Cautions on Antipsychotic Prescribing

APA has released a list of cautionary principles that should be considered when prescribing antipsychotic medications, noting that they are sometimes prescribed inappropriately.…

Beyond Dopamine: Glutamate as a Target in Schizophrenia

An interesting review in ISRN Pharmacology, a peer-reviewed, open access journal, describes that for the last 60 years, antipsychotic pharmacology targeting antagonism of dopamine (DA) D2 receptors have been the primary treatment choice for schizophrenia. The clinical improvement seen …

Experts Convene to Focus on Medication-Development Slowdown

This month the American Psychiatric Association assembled experts from academia, the pharmaceutical industry, venture-capital firms, advocacy groups, and government agencies to discuss the serious decline in the number of medications being developed to treat psychiatric illnesses. The summit was moderated …

Impact of Preexisting Metabolic Risk Factors on the Choice of Antipsychotics

A study in this month’s Psychiatric Services examined the association between patients’ preexisting metabolic risk factors and the physician’s choice of antipsychotic agent based on its propensity to cause metabolic side effects.

Over a span of 3 years, 1,898 office-based …